JP3453188B2 - Method for producing oleanolic acid derivative - Google Patents
Method for producing oleanolic acid derivativeInfo
- Publication number
- JP3453188B2 JP3453188B2 JP10817894A JP10817894A JP3453188B2 JP 3453188 B2 JP3453188 B2 JP 3453188B2 JP 10817894 A JP10817894 A JP 10817894A JP 10817894 A JP10817894 A JP 10817894A JP 3453188 B2 JP3453188 B2 JP 3453188B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- yield
- added
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title description 10
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 67
- -1 hydroxyimino Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 150000001340 alkali metals Chemical class 0.000 claims description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 229910052744 lithium Inorganic materials 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 5
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 95
- 239000000243 solution Substances 0.000 description 40
- 239000000203 mixture Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 7
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940125797 compound 12 Drugs 0.000 description 7
- 229940125898 compound 5 Drugs 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 150000003648 triterpenes Chemical class 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 238000006027 Birch reduction reaction Methods 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QOJLTIJRCYTUDQ-UHFFFAOYSA-N 2-dimethoxyphosphorylacetic acid Chemical compound COP(=O)(OC)CC(O)=O QOJLTIJRCYTUDQ-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 2
- 239000004157 Nitrosyl chloride Substances 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- VPCDQGACGWYTMC-UHFFFAOYSA-N nitrosyl chloride Chemical compound ClN=O VPCDQGACGWYTMC-UHFFFAOYSA-N 0.000 description 2
- 235000019392 nitrosyl chloride Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ADBMMSFXIFGNAX-MDAIVZGXSA-N (3beta)-3,27-dihydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(CO)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C ADBMMSFXIFGNAX-MDAIVZGXSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical class O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- ADSNHKTXYJZXDF-UHFFFAOYSA-N 3-hydroxy-2-nitrobenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1[N+]([O-])=O ADSNHKTXYJZXDF-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000274911 Myrica cerifera Species 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- FXCLIEYDXXVEAI-UHFFFAOYSA-N benzene;dichloromethane Chemical compound ClCCl.C1=CC=CC=C1 FXCLIEYDXXVEAI-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- JHDQHPJHLHKZDL-UHFFFAOYSA-N methyl 4-chloro-4-oxobut-2-enoate Chemical compound COC(=O)C=CC(Cl)=O JHDQHPJHLHKZDL-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- ADBMMSFXIFGNAX-UHFFFAOYSA-N myricerol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(CO)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C ADBMMSFXIFGNAX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は式(I):The present invention relates to the formula (I):
【化4】
(式中、XおよびYは、いずれか一方が水素であって他
方が保護されていてもよいヒドロキシであるか、一緒に
なって保護されていてもよいカルボニルを形成し、R1
はヒドロキシまたはアミノを表す)で示されるオレアノ
ール酸誘導体(以下、化合物(I)という)の新規な製
造方法に関する。[Chemical 4] (In the formula, X and Y are either one of hydrogen and the other of which is optionally protected hydroxy, or together form an optionally protected carbonyl, and R 1
Represents a hydroxy or amino) and relates to a novel method for producing an oleanolic acid derivative (hereinafter referred to as compound (I)).
【0002】[0002]
【従来技術と発明が解決すべき課題】化合物(I)は、
ヒトまたは動物のための医薬を含む、様々な化合物の合
成における中間体として有用であり、例えば、エンドセ
リン受容体拮抗物質としてその有用性が知られている、
下記の式(III):PRIOR ART AND PROBLEMS TO BE SOLVED BY THE INVENTION Compound (I) is
Useful as an intermediate in the synthesis of various compounds, including pharmaceuticals for humans or animals, for example known for their usefulness as endothelin receptor antagonists,
The following formula (III):
【化5】
[式中、R4は水素または代謝性エステル残基、R5は水
素または−R6−R7を表す。但し、R6はSO3、CH2
COO、COCOOまたはCOR8COO(R8は低級ア
ルキレンまたは低級アルケニレン)、R7は水素または
代謝性エステル残基を表す。]で示されるトリテルペン
誘導体の製造中間体である。このトリテルペン誘導体
(III)は、血管収縮作用を有する内皮細胞由来のペ
プチドであるエンドセリンの受容体拮抗剤であり、従っ
て、エンドセリンの過剰分泌に起因する様々な疾患の治
療または予防に特に有効であることが示唆されている
[PCT/JP91/01707(国際公開番号WO9
2/12991)および特願平第5−140416
号]。そのような疾患の例として、高血圧、虚血性心疾
患、脳循環障害、腎障害、諸臓器の循環不全、喘息など
を挙げることができる。[Chemical 5] [In the formula, R 4 represents hydrogen or a metabolizable ester residue, and R 5 represents hydrogen or -R 6 -R 7 . However, R 6 is SO 3 , CH 2
COO, COCOO or COR 8 COO (R 8 is lower alkylene or lower alkenylene), R 7 represents hydrogen or a metabolizable ester residue. ] It is a manufacturing intermediate of the triterpene derivative shown by these. This triterpene derivative (III) is a receptor antagonist of endothelin, which is a peptide derived from endothelial cells having a vasoconstrictor action, and thus is particularly effective for treating or preventing various diseases caused by hypersecretion of endothelin. [PCT / JP91 / 01707 (International Publication Number WO9
2/12991) and Japanese Patent Application No. 5-140416
issue]. Examples of such diseases include hypertension, ischemic heart disease, cerebral circulation disorder, renal disorder, circulatory failure of various organs, asthma and the like.
【0003】このトリテルペン誘導体(III)は、従
来、ミリセロンまたはミリセロール(本明細書中、それ
ぞれ、式(I)において、XおよびYが一緒になってカ
ルボニルを表し、R1がヒドロキシである化合物、並び
にXおよびYの1方がヒドロキシで他方が水素であり、
R1がヒドロキシである化合物を意味するものとする)
から、既知の方法(WO92/12991および特願平
第5−140416号)で製造することができる。例え
ば、ミリセロンに、ジメチルホスホノ酢酸を反応させて
式(IV):This triterpene derivative (III) has heretofore been referred to as myriceron or myricelol (in the present specification, compounds of the formula (I), respectively, in which X and Y together represent carbonyl and R 1 is hydroxy, And one of X and Y is hydroxy and the other is hydrogen,
Shall mean a compound in which R 1 is hydroxy)
Can be produced by a known method (WO92 / 12991 and Japanese Patent Application No. 5-140416). For example, myriceron is reacted with dimethylphosphonoacetic acid to give formula (IV):
【化6】 で示される化合物を得、該化合物と式(V):[Chemical 6] And a compound of the formula (V):
【化7】
(式中、R5は上記と同意義であり、R9はBoc(t−ブ
トキシカルボニル基)などのフェノール保護基または水
素原子を表す)で示されるアルデヒドをホーナーエモン
ズ反応の反応条件下で縮合させ、脱保護および/または
化学修飾を行うことで製造することができる。[Chemical 7] (In the formula, R 5 has the same meaning as above, and R 9 represents a phenol protecting group such as Boc (t-butoxycarbonyl group) or a hydrogen atom), and the aldehyde is condensed under the reaction conditions of the Horner-Emmons reaction. And deprotection and / or chemical modification.
【0004】従来、ミリセロン等の式(I)で示される
化合物は、シロコヤマモモ(Myricacerifera)から抽出
して得られる、ミリセロンまたはミリセロールの誘導体
を化学修飾することにより製造されていた。即ち、シロ
コヤマモモの枝をメタノール等の極性溶媒で数日間抽出
し、さらに、抽出物を水と混和しないクロロホルム等の
有機溶媒を用いて抽出し、得られた抽出物をシリカゲル
カラムクロマトグラフィ−で分離し、得られた物質をさ
らに化学修飾することにより、式(I)の化合物を製造
していた。このように従来法は極めて繁雑な工程を要す
るために、目的物質の収率は極めて低かった。従って、
ミリセロンおよびミリセロール等の式(I)で示される
化合物を、市販品又は、容易に入手可能な原料物質より
の効率良く製造する方法の開発が強く望まれていた。Conventionally, the compounds of the formula such as Miriseron (I) is obtained by extracting from Shirokoyamamomo (Myricacerifera), it has been prepared by chemically modifying the derivative of Miriseron or Miriseroru. That is, the branches of white peaches were extracted with a polar solvent such as methanol for several days, and the extract was extracted with an organic solvent such as chloroform immiscible with water, and the obtained extract was separated by silica gel column chromatography. Then, the compound of formula (I) was produced by further chemically modifying the obtained substance. Thus, the conventional method requires extremely complicated steps, and thus the yield of the target substance was extremely low. Therefore,
It has been strongly desired to develop a method for efficiently producing a compound represented by the formula (I) such as myriceron and myricerol from a commercially available product or an easily available starting material.
【0005】[0005]
【課題を解決するための手段】本発明者らは、ある種の
ラクトンをBirch反応の条件下で還元することにより、
容易に目的の化合物(I)を効率良く製造することがで
きることを見いだし、本発明を完成するに至った。The present inventors have found that by reducing certain lactones under the conditions of the Birch reaction,
It was found that the desired compound (I) can be easily produced efficiently, and the present invention has been completed.
【0006】即ち、本発明は化合物(I)の新規な製造
方法であって、式(II):That is, the present invention is a novel process for producing compound (I), which comprises the formula (II):
【化8】
(式中、XおよびYは、いずれか一方が水素であって他
方が保護されていてもよいヒドロキシであるか、一緒に
なって保護されていてもよいオキソを形成し、R2は酸
素、保護されていてもよいヒドロキシイミノまたは保護
されていてもよいイミノ、R3はエステル型ヒドロキシ
保護基を表す)で示される化合物を、アルカリ金属また
はアルカリ土類金属を用い、アミン溶液中で還元するこ
とを特徴とする方法を提供するものである。本発明方法
に用いられる保護基について説明する。[Chemical 8] (In the formula, X and Y are either hydroxy which may be hydrogen and the other may be protected, or they may together form oxo which may be protected, R 2 is oxygen, A compound represented by optionally protected hydroxyimino or optionally protected imino, R 3 represents an ester type hydroxy protecting group is reduced in an amine solution using an alkali metal or an alkaline earth metal. The present invention provides a method characterized by the above. The protecting group used in the method of the present invention will be described.
【0007】XまたはYにおけるヒドロキシ保護基とし
ては、還元反応に悪影響を及ぼさないものであれば還元
中に脱保護されるものであってもよく、公知のヒドロキ
シ保護基を幅広く使用でき、アラルキル(メトキシベン
ジル、ニトロベンジル、2,4−ジメトキシベンジル、
トリチル等)、アルキルカルボニル(アセチル、ハロゲ
ン化アセチル、ピバロイル、ホルミル、シクロヘキシル
アセチル等)、アリールカルボニル(ベンゾイル、トル
オイル、キシリル、インダニル等)、アルコキシカルボ
ニル(メトキシカルボニル、ヒーブトキシカルボニル、
シクロプロポキシカルボニル等)、アルケニルオキシカ
ルボニル(プロペニルオキシカルボニル等)、アリール
オキシカルボニル(フェノキシカルボニル等)、アラル
キルオキシカルボニル(ニトロベンジルオキシカルボニ
ル等)、シリル型(トリメチルシリル、t−ブチルジメ
チルシリル、ジメチルフェニルシリル、トーブトキシジ
フェニルシリル等)およびエーテル型(アルキルエーテ
ル、アリールエーテル、アラルキルエーテル、メトキシ
メチル、テトラヒドロフラニル等)等が例示される。好
ましくは、アセチル等のアルカノイルである。尚、該ヒ
ドロキシ部分は本還元反応を行うに当たって、保護され
ていなくても何等不都合はない。The hydroxy-protecting group for X or Y may be one that is deprotected during the reduction as long as it does not adversely affect the reduction reaction, and known hydroxy-protecting groups can be widely used. Methoxybenzyl, nitrobenzyl, 2,4-dimethoxybenzyl,
Trityl, etc.), alkylcarbonyl (acetyl, acetyl halide, pivaloyl, formyl, cyclohexylacetyl, etc.), arylcarbonyl (benzoyl, toluoyl, xylyl, indanyl, etc.), alkoxycarbonyl (methoxycarbonyl, hebutoxycarbonyl, etc.)
Cyclopropoxycarbonyl etc.), alkenyloxycarbonyl (propenyloxycarbonyl etc.), aryloxycarbonyl (phenoxycarbonyl etc.), aralkyloxycarbonyl (nitrobenzyloxycarbonyl etc.), silyl type (trimethylsilyl, t-butyldimethylsilyl, dimethylphenylsilyl) , Tobutoxydiphenylsilyl, etc.) and ether type (alkyl ether, aryl ether, aralkyl ether, methoxymethyl, tetrahydrofuranyl, etc.) and the like. Preferred is alkanoyl such as acetyl. It should be noted that there is no inconvenience in carrying out the present reduction reaction even if the hydroxy moiety is not protected.
【0008】XおよびYにおける、保護されていてもよ
いオキソにおける保護基としては、還元反応に悪影響を
及ぼさないものであれば公知のカルボニル保護基を幅広
く使用できるが、好ましくは、還元反応中に脱保護され
ず反応後に公知の方法により容易に脱保護されるもので
あり、ジアルキルアセタール型(ジメチルアセタール、
ジエチルアセタール等)、アルキレンジオキシ型(エチ
レンジオキシ、プロピレンジオキシ等)およびアルキレ
ンジチオ型(エチレンジチオ、プロピレンジチオ等)等
が例示され、特に好ましくは、アルキレンジオキシ型で
ある。尚、XおよびYが保護されていないオキソである
場合には、本反応によりヒドロキシに還元された化合物
(I)の三位ヒドロキシ体が主生成物として得られる場
合があるが、該ヒドロキシ体は、例えば、特願平5−1
40416号に記載の方法により容易に三位オキソ体に
変換することが出来る。R2におけるヒドロキシイミノ
の保護基としては、還元反応に悪影響を及ぼさないもの
であれば還元中に脱保護されるものであってもよく、前
記ヒドロキシ保護基のうち、アルキルカルボニル、アル
コキシカルボニル、エーテル型が挙げられる。該ヒドロ
キシ部分は本還元反応を行うに当たって保護されていな
くても何等不都合はない。As the protecting group for oxo which may be protected in X and Y, any known carbonyl protecting group can be widely used as long as it does not adversely affect the reduction reaction, but preferably during the reduction reaction. It is not deprotected and is easily deprotected by a known method after the reaction, and is a dialkyl acetal type (dimethyl acetal,
Examples thereof include diethyl acetal), alkylenedioxy type (ethylenedioxy, propylenedioxy, etc.) and alkylenedithio type (ethylenedithio, propylenedithio, etc.), and the like, and alkylenedioxy type is particularly preferable. When X and Y are unprotected oxo, the 3-position hydroxy form of compound (I) reduced to hydroxy may be obtained as the main product by this reaction. For example, Japanese Patent Application No. 5-1
It can be easily converted into the 3-position oxo form by the method described in No. 40416. The hydroxyimino protecting group for R 2 may be one that is deprotected during reduction as long as it does not adversely affect the reduction reaction, and among the above hydroxy protecting groups, alkylcarbonyl, alkoxycarbonyl, ether There are types. There is no problem even if the hydroxy moiety is not protected in carrying out the present reduction reaction.
【0009】R2におけるイミノの保護基としては、還
元反応に悪影響を及ぼさないものであれば還元中に脱保
護されるものであってもよく、公知のイミノ保護基を幅
広く使用できるが、好ましくはアルキル(エチル、t−
ブチル等)である。R3におけるエステル型ヒドロキシ
保護基としては、還元反応により容易に離脱してかつ反
応に悪影響を及ぼさないものでなければならず、前記ヒ
ドロキシ保護基のうちアルキルカルボニル、アリールカ
ルボニル、アルコキシカルボニル、アリールオキシカル
ボニルが挙げられる。尚、本還元反応後、化合物(I)
に上記いずれかの保護基が残存する場合には、所望によ
り、当業者に周知の方法により脱保護することが出来
る。本還元反応に係る化合物(I)及び(II)は、ト
リテルペン類の中でもβ−アミリン型の骨格を有する。
本反応においては、Birch反応条件を利用することによ
り、化合物(II)の27位側鎖並びに12位及び13
位部分を1工程で還元でき、化合物(I)を高収率で得
ることが出来る。The imino protecting group for R 2 may be one that is deprotected during the reduction as long as it does not adversely affect the reduction reaction, and known imino protecting groups can be widely used, but are preferred. Is alkyl (ethyl, t-
Butyl etc.). The ester-type hydroxy protecting group for R 3 must be one that can be easily removed by a reduction reaction and does not adversely affect the reaction, and among the above-mentioned hydroxy protecting groups, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy. Carbonyl. After the reduction reaction, the compound (I)
If any of the above protecting groups remains, it can be deprotected by a method well known to those skilled in the art, if desired. The compounds (I) and (II) involved in the present reduction reaction have a β-amyrin type skeleton among triterpenes.
In this reaction, by utilizing the Birch reaction condition, the 27-position side chain of compound (II) and the 12-position and 13-position
The position moiety can be reduced in one step, and compound (I) can be obtained in high yield.
【0010】Birch反応は、通常アミン溶液中、アルカ
リ金属またはアルカリ土類金属を用いて行う還元反応で
あり、その反応条件は当業者に既知であって、多くの文
献に記載されている[例えば、新実験化学講座15「酸
化と還元II」第1章、第165頁(1976年)、お
よび有機化学実験のてびき[3]合成反応(I)東京化
学同人(1990年)40−42頁]。即ち、Birch還
元に用いられるアルカリ金属またはアルカリ土類金属と
しては、リチウム、カリウム、ナトリウム、カルシウ
ム、マグネシウム、を挙げることができ、本発明方法に
おいては、リチウム、ナトリウム、カルシウムが好まし
い。 アミン溶液としては液体アンモニアまたはメチル
アミン、エチルアミン、エチレンジアミン、ジメチルア
ミン、ジエチルアミン等のモノ又はジ低級アルキルアミ
ンを用いることができ、本発明方法においては、液体ア
ンモニアが特に好ましい。The Birch reaction is a reduction reaction usually carried out with an alkali metal or alkaline earth metal in an amine solution, the reaction conditions of which are known to those skilled in the art and described in many literatures [eg. , New Experimental Chemistry Course 15 "Oxidation and Reduction II", Chapter 1, 165 (1976), and Tebiki [3] Synthetic Reaction of Organic Chemistry (I) Tokyo Kagaku Dojin (1990), pp. 40-42. ]. That is, examples of the alkali metal or alkaline earth metal used for the Birch reduction include lithium, potassium, sodium, calcium and magnesium, and lithium, sodium and calcium are preferable in the method of the present invention. As the amine solution, liquid ammonia or mono- or di-lower alkylamine such as methylamine, ethylamine, ethylenediamine, dimethylamine and diethylamine can be used, and liquid ammonia is particularly preferable in the method of the present invention.
【0011】通常、2当量以上のアルカリ金属またはア
ルカリ土類金属の存在下、所望により、メタノール、エ
タノール、イソプロパノール、t−ブタノールなどのプ
ロトン供与体(アニオン捕捉剤)の存在下で、好ましく
は無水条件下で反応させる。本発明方法においては、プ
ロトン供与体として、無水エタノールが特に好ましい。
反応溶媒としては、アミン溶液だけでもよいが、所望
によりエーテル、テトラヒドロフラン、ジメトキシエタ
ンなどの補助溶媒を併用しても良い。反応温度は、通
常、氷冷下〜−100℃、好ましくは−50〜−80℃
である。反応後、減圧濃縮し、中和し、有機溶媒で抽出
し、乾燥、濃縮し、シリカゲル、アルミナ等のカラムク
ロマトグラフィーで精製することにより、目的化合物
(I)を得ることができる。Usually, in the presence of 2 equivalents or more of an alkali metal or an alkaline earth metal, if desired, in the presence of a proton donor (anion scavenger) such as methanol, ethanol, isopropanol or t-butanol, preferably anhydrous. React under conditions. In the method of the present invention, anhydrous ethanol is particularly preferable as the proton donor.
The reaction solvent may be an amine solution alone, but if desired, an auxiliary solvent such as ether, tetrahydrofuran or dimethoxyethane may be used in combination. The reaction temperature is generally under ice cooling to -100 ° C, preferably -50 to -80 ° C.
Is. After the reaction, concentration under reduced pressure, neutralization, extraction with an organic solvent, drying, concentration, and purification by column chromatography on silica gel, alumina, etc., the target compound (I) can be obtained.
【0012】式(II)で示されるラクトンは、例え
ば、オレアノール酸等を出発原料に当業者既知の方法
[例、D.H.R. Barton et al., Tetrahedron, Supplemen
t No. 7,pp.57-67 (1965)]に従って製造することがで
きる。なお、式(II)において、XおよびYのいずれ
か一方が水素であって他方が保護されていてもよいヒド
ロキシであり、R2がオキソ、保護されていてもよいヒ
ドロキシイミノまたは保護されていてもよいイミノ、R
3が水素またはエステル型ヒドロキシ保護基である化合
物は新規であり、本発明の製造方法の有用な中間体であ
る。本発明方法によれば、従来法と比較して用いる溶媒
の量が格段に少なく、工程も簡単であるために、時間、
労力の節約が可能となり、しかも化合物(I)を高収率
で得ることができるので、最終目的物質の製造効率を飛
躍的に向上し得る。従って、本発明の方法は、式(I)
で示される任意の化合物を用いる製造工程の効率の改善
に広く有用である。The lactone represented by the formula (II) can be obtained by, for example, using oleanolic acid or the like as a starting material by a method known to those skilled in the art [eg, DHR Barton et al., Tetrahedron, Supplemen.
t No. 7, pp. 57-67 (1965)]. In formula (II), one of X and Y is hydrogen and the other is optionally protected hydroxy, and R 2 is oxo, optionally protected hydroxyimino or protected. Good imino, R
The compound in which 3 is hydrogen or an ester-type hydroxy protecting group is novel and is a useful intermediate in the production method of the present invention. According to the method of the present invention, the amount of the solvent used is significantly smaller than that of the conventional method, and the process is simple.
Since labor can be saved and the compound (I) can be obtained in high yield, the production efficiency of the final target substance can be dramatically improved. Accordingly, the method of the present invention comprises the formula (I)
It is widely useful for improving the efficiency of the production process using any compound represented by.
【0013】[0013]
【実施例】以下に実施例を挙げ、本発明を詳しく説明す
るが、これらの実施例は本発明を制限するものではな
い。実施例1
ミリセロンの製造The present invention will be described in detail below with reference to examples, but these examples do not limit the present invention. Example 1 Production of myriceron
【化9】 [Chemical 9]
【化10】 [Chemical 10]
【0014】1) 化合物2の合成
オレアノール酸1(10.0g、21.9mmol)をクロロホ
ルム(150ml)−アセトン(500ml)混液に溶解し、氷
冷下、Jones試薬((CrO3/アセトン/H2SO4)1
6ml、42.7mmol)を加え、30分攪拌する。2−プロ
パノール(2.0ml)を加え、過剰の試薬を分解した後、
水(50ml)を加え減圧下に濃縮する。残渣を酢酸エチル
(200ml×2)で抽出し、食塩水で洗浄した後、無水硫
酸ナトリウムで乾燥し、減圧下に溶媒を留去して結晶性
の粗生成物2を得た。収量9.95g(21.9mmol)、収
率100%。化合物2
:
TLC Rf=0.43(ヘキサン/酢酸エチル=2/1)1
H NMR(CDCl3)δppm; 0.81(3H,s),0.9
1(3H,s),0.93(3H,s),1.03(3H,s),1.05
(3H,s),1.08(3H,s),1.14(3H,s),2.84
(1H,dd,J=13.0,4.0Hz),5.30(1H,dd,J
=3.5,3.5Hz)1) Synthesis of Compound 2 Oleanolic acid 1 (10.0 g, 21.9 mmol) was dissolved in a mixed solution of chloroform (150 ml) -acetone (500 ml) and cooled under ice-cold Jones reagent ((CrO 3 / acetone / H. 2 SO 4 ) 1
6 ml, 42.7 mmol) are added and stirred for 30 minutes. After adding 2-propanol (2.0 ml) to decompose excess reagent,
Water (50 ml) is added and the mixture is concentrated under reduced pressure. The residue is ethyl acetate
It was extracted with (200 ml × 2), washed with brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain a crystalline crude product 2 . Yield 9.95 g (21.9 mmol), 100% yield. Compound 2 : TLC Rf = 0.43 (hexane / ethyl acetate = 2/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.81 (3H, s), 0.9
1 (3H, s), 0.93 (3H, s), 1.03 (3H, s), 1.05
(3H, s), 1.08 (3H, s), 1.14 (3H, s), 2.84
(1H, dd, J = 13.0,4.0Hz), 5.30 (1H, dd, J
= 3.5,3.5Hz)
【0015】2) 化合物3の合成
粗生成物2(9.95g、21.9mmol)を塩化メチレン(3
00ml)−メタノール(30ml)混液に溶解し、−60℃
以下に冷却する。オゾンガスを溶液が紫色に着色するま
で導入する。次いで、窒素ガスをバブリングさせ過剰の
オゾンを除去後ジメチルスルフィド(2.0ml)を加え室
温で1時間攪拌した。減圧下溶媒を留去し、残渣を2−
プロパノールより結晶化させ化合物3を得た。収量9.
24g(19.7mmol)、収率90%。化合物3
:
TLC Rf=0.42(塩化メチレン/酢酸エチル=9
/1)1
H NMR(CDCl3)δppm; 0.91(3H,s),0.9
9(6H,s),1.05(3H,s),1.10(3H,s),1.19
(3H,s),1.32(3H,s),3.91(1H,br s)2) Synthesis of compound 3 Crude product 2 (9.95 g, 21.9 mmol) was converted to methylene chloride (3
(00 ml) -dissolved in methanol (30 ml) mixture, -60 ° C
Cool to: Ozone gas is introduced until the solution turns purple. Then, nitrogen gas was bubbled to remove excess ozone, dimethyl sulfide (2.0 ml) was added, and the mixture was stirred at room temperature for 1 hour. The solvent was distilled off under reduced pressure, and the residue was treated with 2-
Crystallization from propanol gave compound 3 . Yield 9.
24 g (19.7 mmol), yield 90%. Compound 3 : TLC Rf = 0.42 (methylene chloride / ethyl acetate = 9
/ 1) 1 H NMR (CDCl 3 ) δ ppm ; 0.91 (3H, s), 0.9
9 (6H, s), 1.05 (3H, s), 1.10 (3H, s), 1.19
(3H, s), 1.32 (3H, s), 3.91 (1H, br s)
【0016】3) 化合物4の合成
化合物3(3.24g、6.9mmol)を乾燥ピリジン(50m
l)に溶解し、−40℃に冷却する。ニトロシルクロライ
ド(1.81g、27.6mmol)を窒素ガスと共に導入し、
同温度にて30分間攪拌した。氷水(100ml)を加え、
析出晶を吸引濾取し、水(40ml×2)で洗浄した後、減
圧乾燥を行ない粉末状の化合物4を得た。収量3.40g
(3.40mmol)、収率99%。化合物4
:
TLC Rf=0.76(塩化メチレン/酢酸エチル=9
/1)1
H NMR(CDCl3)δppm; 0.77(3H,s),0.9
5(3H,s),1.01(3H,s),1.06(3H,s),1.11
(3H,s),1.17(3H,s),1.28(3H,s),5.64
(1H,dd,J=3.5,2.0Hz)3) Synthesis of Compound 4 Compound 3 (3.24 g, 6.9 mmol) was dried with pyridine (50 m).
Dissolve in l) and cool to -40 ° C. Nitrosyl chloride (1.81 g, 27.6 mmol) was introduced with nitrogen gas,
The mixture was stirred at the same temperature for 30 minutes. Add ice water (100 ml),
The precipitated crystals were collected by suction filtration, washed with water (40 ml × 2), and dried under reduced pressure to obtain powdery compound 4 . Yield 3.40g
(3.40 mmol), yield 99%. Compound 4 : TLC Rf = 0.76 (methylene chloride / ethyl acetate = 9
/ 1) 1 H NMR (CDCl 3 ) δ ppm ; 0.77 (3H, s), 0.9
5 (3H, s), 1.01 (3H, s), 1.06 (3H, s), 1.11
(3H, s), 1.17 (3H, s), 1.28 (3H, s), 5.64
(1H, dd, J = 3.5,2.0Hz)
【0017】4) 化合物5の合成
化合物4(20.0g,40.1mmol)の乾燥塩化メチレン
(1.00L)溶液に窒素ガスを10分間バブリングを行
った後、氷冷する。同温度にて窒素バブリング下、高圧
水銀ランプ(450W)を1時間20分照射した。反応液
は減圧下溶媒を留去し、残渣に1,2−ジクロロエタン
(200ml)を加え1.5時間加熱還流した。室温に放冷
ののち、析出晶を吸引濾取し粗生成物(10.6g)を得
た。このものを1,2−ジクロロエタン(80ml)に懸濁
し、加熱した後室温まで放冷した。析出晶を濾取し、無
定形の粉末として化合物5を得た。収量9.41g(18.
8mmol)、収率47%。化合物5
:
TLC Rf=0.11(塩化メチレン/酢酸エチル=9
/1)1
H NMR(CDCl3)δppm; 0.90(3H,s),0.9
5(3H,s),0.98(3H,s),1.03(3H,s),1.07
(3H,s),1.26(3H,s),3.88(1H,br d,J=6.
0Hz)4.20(1H,br d,J=6.0Hz),7.60(1
H,s),8.12(1H,s)4) Synthesis of Compound 5 Compound 4 (20.0 g, 40.1 mmol) in dry methylene chloride
After bubbling nitrogen gas into the (1.00 L) solution for 10 minutes, the solution was cooled with ice. At the same temperature, a high pressure mercury lamp (450 W) was irradiated for 1 hour and 20 minutes under nitrogen bubbling. The reaction mixture was evaporated under reduced pressure to remove the solvent, and 1,2-dichloroethane was added to the residue.
(200 ml) was added and the mixture was heated under reflux for 1.5 hours. After cooling to room temperature, the precipitated crystals were collected by suction filtration to obtain a crude product (10.6 g). This product was suspended in 1,2-dichloroethane (80 ml), heated and allowed to cool to room temperature. The precipitated crystals were collected by filtration to obtain compound 5 as an amorphous powder. Yield 9.41g (18.
8 mmol), yield 47%. Compound 5 : TLC Rf = 0.11 (methylene chloride / ethyl acetate = 9
/ 1) 1 H NMR (CDCl 3 ) δ ppm ; 0.90 (3H, s), 0.9
5 (3H, s), 0.98 (3H, s), 1.03 (3H, s), 1.07
(3H, s), 1.26 (3H, s), 3.88 (1H, br d, J = 6.
0Hz) 4.20 (1H, br d, J = 6.0Hz), 7.60 (1
H, s), 8.12 (1H, s)
【0018】4) 化合物6の合成
化合物5(20.0g,40mmol)のジオキサン(300ml)
溶液に酢酸アンモニウム(40.0g,519mmol)、50
%酢酸水溶液(60ml)を加え、氷冷下、三塩化チタン水
溶液(96ml)を滴下する。室温で2時間攪拌後、氷水
(500ml)−酢酸エチル(800ml)混液にあけ、炭酸水
素ナトリウム(270g)にて中和した。有機層を分液
し、水層は酢酸エチル(600ml)で再抽出し、それぞれ
の有機層を食塩水で洗浄した後無水硫酸マグネシウムで
乾燥した。減圧下溶媒を留去し、残渣を酢酸エチルから
結晶化させ粉末状の化合物6を得た。収量16.1g(3
3mmol)、収率83%。化合物6
:
TLC Rf=0.20(n−ヘキサン/酢酸エチル=1/
1)1
H NMR(CDCl3)δppm; 0.89(3H,s),0.9
2(3H,s),0.99(3H,s),1.02(3H,s),1.05
(3H,s),1.30(3H,s),3.76(1H,br d,J=1
0.3Hz),6.99(1H,br d,J=10.0Hz),8.1
1(1H,br d,J=14.8Hz)4) Synthesis of Compound 6 Compound 5 (20.0 g, 40 mmol) in dioxane (300 ml)
Ammonium acetate (40.0 g, 519 mmol), 50 in solution
% Acetic acid aqueous solution (60 ml) is added, and an aqueous titanium trichloride solution (96 ml) is added dropwise under ice cooling. After stirring at room temperature for 2 hours, ice water
The mixture was poured into a mixed solution of (500 ml) -ethyl acetate (800 ml) and neutralized with sodium hydrogen carbonate (270 g). The organic layer was separated, the aqueous layer was re-extracted with ethyl acetate (600 ml), each organic layer was washed with brine and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was crystallized from ethyl acetate to obtain powdery compound 6 . Yield 16.1g (3
3 mmol), yield 83%. Compound 6 : TLC Rf = 0.20 (n-hexane / ethyl acetate = 1 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.89 (3H, s), 0.9
2 (3H, s), 0.99 (3H, s), 1.02 (3H, s), 1.05
(3H, s), 1.30 (3H, s), 3.76 (1H, br d, J = 1
0.3Hz), 6.99 (1H, br d, J = 10.0Hz), 8.1
1 (1H, br d, J = 14.8Hz)
【0019】5) 化合物8の合成
化合物6(25.37g,53mmol)を1,4−ジオキサン
(500ml)に懸濁し、亜硝酸ナトリウム(36.2g,5
25mmol)と酢酸ナトリウム(36.2g,441mmol)を
加え、攪拌下15℃で50%酢酸水溶液(150ml)を2
0分間で滴下した。室温下、40分攪拌後、反応液を減
圧濃縮し、残渣に酢酸エチル(260ml)と水(300ml)
を加え、次いで炭酸ナトリウム(67g)にて中和した。
混合物を酢酸エチル(400ml×2)で抽出し、酢酸エチ
ル層を食塩水で洗浄の後、硫酸ナトリウムで乾燥し、減
圧下溶媒を留去して化合物7(副生成物)と新規化合物
8との混合物(28.2g)を得た。この混合物をテトラヒ
ドロフラン−メタノール混液(3:2、280ml)にて加
温溶解し、室温下、2N水酸化カリウム水溶液(20ml)
を加え40分攪拌した。反応液を2N塩酸水溶液(10m
l)で中和した後減圧濃縮し、残渣を塩化メチレン(20
0ml,100ml)で抽出した。有機層を食塩水で洗浄の
後、硫酸ナトリウムで乾燥し、減圧下溶媒を留去し、残
渣を2−プロパノールより結晶化させ化合物8を得た。
収量22.9g(47mmol)、収率90%。化合物7
:
TLC Rf=0.53(n−ヘキサン/酢酸エチル=1/
1)化合物8
:
TLC Rf=0.40(n−ヘキサン/酢酸エチル=1/
1)1
H NMR(CDCl3)δppm; 0.90(3H,s),0.9
4(3H,s),0.98(3H,s),1.02(3H,s),1.06
(3H,s),1.26(3H,s),3.55(1H,d,J=8.5
Hz),3.94(1H,br d,J=8.5Hz),10.01(1
H,s)5) Synthesis of Compound 8 Compound 6 (25.37 g, 53 mmol) was added to 1,4-dioxane.
Suspended in (500 ml) and sodium nitrite (36.2 g, 5
25 mmol) and sodium acetate (36.2 g, 441 mmol) were added, and 50% acetic acid aqueous solution (150 ml) was added to the mixture at 15 ° C. under stirring to 2 times.
It was dripped in 0 minutes. After stirring at room temperature for 40 minutes, the reaction solution was concentrated under reduced pressure, and ethyl acetate (260 ml) and water (300 ml) were added to the residue.
Was added and then neutralized with sodium carbonate (67 g).
The mixture was extracted with ethyl acetate (400 ml x 2), the ethyl acetate layer was washed with brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give compound 7 (by-product) and the novel compound.
A mixture with 8 (28.2 g) was obtained. This mixture was dissolved by heating in a tetrahydrofuran-methanol mixture (3: 2, 280 ml), and at room temperature, 2N aqueous potassium hydroxide solution (20 ml) was added.
Was added and stirred for 40 minutes. The reaction solution was a 2N aqueous hydrochloric acid solution (10 m
It was neutralized with l) and concentrated under reduced pressure. The residue was diluted with methylene chloride (20
It was extracted with 0 ml and 100 ml). The organic layer was washed with brine, dried over sodium sulfate, the solvent was evaporated under reduced pressure, and the residue was crystallized from 2-propanol to obtain compound 8 .
Yield 22.9 g (47 mmol), yield 90%. Compound 7 : TLC Rf = 0.53 (n-hexane / ethyl acetate = 1 /
1) Compound 8 : TLC Rf = 0.40 (n-hexane / ethyl acetate = 1 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.90 (3H, s), 0.9
4 (3H, s), 0.98 (3H, s), 1.02 (3H, s), 1.06
(3H, s), 1.26 (3H, s), 3.55 (1H, d, J = 8.5
Hz), 3.94 (1H, br d, J = 8.5Hz), 10.01 (1
H, s)
【0020】6) 化合物9の合成
化合物8(25.0g,52mmol)のトルエン(500ml)懸
濁液にエチレングリコール(29ml,520mmol)とピリ
ジウム−p−トルエンスルホン酸(650mg,2.6mmol)
を加え、モレキュラーシーブを充填した脱水装置を付し
て1時間加熱還流した。反応液は冷後、トルエン(25
0ml)で希釈し、水(250ml)および食塩水(200ml)
で順次洗浄した後、硫酸ナトリウムで乾燥し、減圧下溶
媒を留去して結晶性の粗生成物9を得た。収量27.1
3g(51mmol)、収率99%。化合物9
:
TLC Rf=0.38(塩化メチレン/酢酸エチル=9
/1)1
H NMR(CDCl3)δppm; 0.79(3H,s),0.8
9(3H,s),0.90(3H,s),0.94(6H,s),1.21
(3H,s),3.26(1H,d,J=7.5Hz),3.94(5
H,m),10.03(1H,s)6) Synthesis of compound 9 A suspension of compound 8 (25.0 g, 52 mmol) in toluene (500 ml) was added to ethylene glycol (29 ml, 520 mmol) and pyridinium-p-toluenesulfonic acid (650 mg, 2.6 mmol).
Was added and the mixture was heated under reflux for 1 hour with a dehydrator filled with molecular sieves. After cooling the reaction solution, toluene (25
0 ml), diluted with water (250 ml) and saline (200 ml)
After that, it was dried over sodium sulfate and the solvent was distilled off under reduced pressure to obtain a crystalline crude product 9 . Yield 27.1
3 g (51 mmol), yield 99%. Compound 9 : TLC Rf = 0.38 (methylene chloride / ethyl acetate = 9
/ 1) 1 H NMR (CDCl 3 ) δ ppm ; 0.79 (3H, s), 0.8
9 (3H, s), 0.90 (3H, s), 0.94 (6H, s), 1.21
(3H, s), 3.26 (1H, d, J = 7.5Hz), 3.94 (5
H, m), 10.03 (1H, s)
【0021】7) 化合物10の合成
化合物9(25.4g,48mmol)の乾燥ピリジン(80ml)
溶液に無水酢酸(20ml,200mmol)と4−ジメチルア
ミノピリジン(290mg,2.4mmol)を加え、60℃で
30分攪拌した。反応液は冷後、氷水(500ml)を加
え、析出晶を吸引濾取し、水(100ml×3)で洗浄した
後、風乾した。粗生成物をメタノール(100ml)に懸濁
し、60℃で5分加温し室温に放冷した。析出晶を吸引
濾取して粉末状の新規化合物10を得た。収量25.9
3g(45.5mmol)、収率95%。化合物10
:
TLC Rf=0.46(塩化メチレン/酢酸エチル=1
9/1)1
H NMR(CDCl3)δppm; 0.80(6H,s),0.9
0(3H,s),0.92(3H,s),0.94(3H,s),1.21
(3H,s),2.12(3H,s),3.95(4H,m),5.26
(1H,dd,J=2.8,2.8Hz),10.23(1H,s)7) Synthesis of compound 10 Compound 9 (25.4 g, 48 mmol) in dry pyridine (80 ml)
Acetic anhydride (20 ml, 200 mmol) and 4-dimethylaminopyridine (290 mg, 2.4 mmol) were added to the solution, and the mixture was stirred at 60 ° C for 30 minutes. After cooling the reaction solution, ice water (500 ml) was added, and the precipitated crystals were collected by suction filtration, washed with water (100 ml × 3), and then air-dried. The crude product was suspended in methanol (100 ml), heated at 60 ° C. for 5 minutes and allowed to cool to room temperature. The precipitated crystals were collected by suction filtration to obtain powdery novel compound 10 . Yield 25.9
3 g (45.5 mmol), yield 95%. Compound 10 : TLC Rf = 0.46 (methylene chloride / ethyl acetate = 1
9/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.80 (6H, s), 0.9
0 (3H, s), 0.92 (3H, s), 0.94 (3H, s), 1.21
(3H, s), 2.12 (3H, s), 3.95 (4H, m), 5.26
(1H, dd, J = 2.8,2.8Hz), 10.23 (1H, s)
【0022】8) 化合物11の合成
−78℃に冷却した液体アンモニア(300ml)に金属リ
チウム(1.84g,263mmol)を加え30分攪拌溶解す
る。この中へ化合物10(30g、53mmol)の無水テト
ラヒドロフラン(300ml)溶液を45分にて滴下し、同
温度にて1時間攪拌した。次いで無水エタノール(15m
l)を滴下し、室温に放置してアンモニアを除去した後減
圧濃縮する。残渣に水(150ml)および塩化メチレン
(400ml)を加え、激しく攪拌下2N塩酸水溶液にてp
H4に調整する。有機層を分液し、水層は塩化メチレン
(200ml)で再抽出する。それぞれの有機層は水および
食塩水で順次洗浄し、硫酸マグネシウムで乾燥した後、
減圧濃縮する。油状残渣は酢酸エチル−n−ヘキサンよ
り結晶化させ化合物11を得た。
収量23.2g(45mmol)、収率86%化合物11
:
TLC Rf=0.40(塩化メチレン/酢酸エチル=9
/1)1
H NMR(CDCl3)δppm; 0.70(3H,s),0.8
3(3H,s),0.90(3H,s),091(3H,s),0.92
(3H,s),0.96(3H,s),2.92(1H,dd,J=13.
0,4.0Hz),3.16(1H,d,J=11.8Hz),3.7
8(1H,d,J=11.8Hz),3.93(4H,br s),5.8
3(1H,br s)8) Synthesis of compound 11 Lithium metal (1.84 g, 263 mmol) was added to liquid ammonia (300 ml) cooled to −78 ° C. and dissolved with stirring for 30 minutes. A solution of compound 10 (30 g, 53 mmol) in anhydrous tetrahydrofuran (300 ml) was added dropwise thereto over 45 minutes, and the mixture was stirred at the same temperature for 1 hour. Then absolute ethanol (15m
l) is added dropwise, the mixture is left at room temperature to remove ammonia, and then concentrated under reduced pressure. Water (150 ml) and methylene chloride on the residue
(400 ml) was added, and the mixture was stirred vigorously with 2N aqueous hydrochloric acid to p
Adjust to H4. The organic layer is separated and the aqueous layer is methylene chloride.
Re-extract with (200 ml). Each organic layer was washed successively with water and brine, dried over magnesium sulfate,
Concentrate under reduced pressure. The oily residue was crystallized from ethyl acetate-n-hexane to give compound 11 . Yield 23.2 g (45 mmol), yield 86% Compound 11 : TLC Rf = 0.40 (methylene chloride / ethyl acetate = 9
/ 1) 1 H NMR (CDCl 3 ) δ ppm ; 0.70 (3H, s), 0.8
3 (3H, s), 0.90 (3H, s), 091 (3H, s), 0.92
(3H, s), 0.96 (3H, s), 2.92 (1H, dd, J = 13.
0,4.0Hz), 3.16 (1H, d, J = 11.8Hz), 3.7
8 (1H, d, J = 11.8Hz), 3.93 (4H, br s), 5.8
3 (1H, br s)
【0023】9) 化合物12(ミリセロン)の合成
化合物11(515mg、1mmol)のテトラヒドロン(2.5
ml)溶液に2N塩酸(0.5ml)を加え、1時間加熱還流す
る。この反応液に水(5ml)、塩化メチレン(10ml)を加
え攪拌静置後、有機層を分取し、水層は塩化メチレンで
再抽出する。それぞれの有機層は、食塩水で洗浄し、硫
酸マグネシウムで乾燥後、減圧濃縮する。残渣は、塩化
メチレン−メタノールより結晶化させ、化合物12を得
た。収量374mg(0.79mmol)、収率79%。化合物12
:
TLC Rf=0.57(n−ヘキサン/酢酸エチル=1/
1)1
H NMR(CDCl3)δppm; 0.79(3H,s),0.9
4(3H,s),0.98(3H,s),1.03(6H,s),1.11
(3H,s),2.3〜2.6(2H,m),2.96(1H,dd,J=
13.2,3.8Hz),3.26(1H,d,J=11.8Hz),
3.81(1H,d,J=11.8Hz),5.89(1H,br s)9) Synthesis of compound 12 (myriceron) Compound 11 (515 mg, 1 mmol) tetrahydrone (2.5
2N hydrochloric acid (0.5 ml) is added to the solution) and the mixture is heated under reflux for 1 hour. Water (5 ml) and methylene chloride (10 ml) were added to this reaction solution, the mixture was left standing with stirring, the organic layer was separated, and the aqueous layer was reextracted with methylene chloride. Each organic layer is washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was crystallized from methylene chloride-methanol to obtain compound 12 . Yield 374 mg (0.79 mmol), yield 79%. Compound 12 : TLC Rf = 0.57 (n-hexane / ethyl acetate = 1 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.79 (3H, s), 0.9
4 (3H, s), 0.98 (3H, s), 1.03 (6H, s), 1.11
(3H, s), 2.3 to 2.6 (2H, m), 2.96 (1H, dd, J =
13.2, 3.8 Hz), 3.26 (1 H, d, J = 11.8 Hz),
3.81 (1H, d, J = 11.8Hz), 5.89 (1H, br s)
【0024】実施例2 ミリセロールの製造 Example 2 Production of millicerol
【化11】 [Chemical 11]
【化12】 [Chemical 12]
【0025】1) 化合物2’の合成
原料のオレアノール酸1(32.42g,71mmol)をピリ
ジン(260ml)に溶かし、室温下、無水酢酸(36.2
g,355mmol)を滴下する。次いで、4−ジメチルアミ
ノピリジン(867mg,7mmol)を加え、室温下、1時間
攪拌する。その後、氷冷下、メタノール(20ml)を流入
し、室温で30分攪拌する。水(400ml)を加えてスラ
リーとし、濾過を行う。得た粗晶を、塩化メチレン(3
00ml)に再溶解し、1N塩酸(110ml)に加える。有
機層を分取し、水層は、塩化メチレンで抽出する。それ
ぞれの有機層を食塩水で洗浄した後、無水硫酸マグネシ
ウムで乾燥し、濃縮して粗生成物2’を得る。収量3
5.93g(72mmol)、収率100%化合物2’:
TLC Rf=0.64(クロロホルム/酢酸エチル=1
5/1)1
H NMR(CDCl3)δppm; 0.74(s,3H),0.8
5(s,3H),0.86(s,3H),0.90(s,3H),0.93
(s,3H),0.94(s,3H),1.13(s,3H),1.0〜
2.0(m,22H),2.05(s,3H),2.82(dd,J=1
4.0,4.0Hz,1H),4.50(dd,J=7.8,7.8H
z,1H),5.27(br s,1H)[0025] 1) Compound 2 oleanolic acid 1 starting materials for synthesis of '(32.42G, dissolved 71 mmol) in pyridine (260 ml), at room temperature, acetic anhydride (36.2
g, 355 mmol) is added dropwise. Then, 4-dimethylaminopyridine (867 mg, 7 mmol) is added, and the mixture is stirred at room temperature for 1 hour. Then, methanol (20 ml) was introduced under ice cooling, and the mixture was stirred at room temperature for 30 minutes. Water (400 ml) is added to form a slurry and filtration is performed. The crude crystals obtained were mixed with methylene chloride (3
Redissolved in 00 ml) and added to 1N hydrochloric acid (110 ml). The organic layer is separated and the aqueous layer is extracted with methylene chloride. Each organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated to obtain a crude product 2 '. Yield 3
5.93 g (72 mmol), yield 100% Compound 2 ′: TLC Rf = 0.64 (chloroform / ethyl acetate = 1
5/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.74 (s, 3H), 0.8
5 (s, 3H), 0.86 (s, 3H), 0.90 (s, 3H), 0.93
(s, 3H), 0.94 (s, 3H), 1.13 (s, 3H), 1.0
2.0 (m, 22H), 2.05 (s, 3H), 2.82 (dd, J = 1
4.0, 4.0Hz, 1H), 4.50 (dd, J = 7.8, 7.8H
z, 1H), 5.27 (br s, 1H)
【0026】2) 化合物3’の合成
粗生成物2’(35.93g,72mmol)を塩化メチレン
(360ml)−メタノール(50ml)混液に溶かし、−60
℃以下に冷却する。冷却下、オゾンガスを溶液が紫色に
変わるまで導入する。次いで、窒素ガスをバブリングさ
せ、過剰のオゾンを除去(退色)後、濃縮する。容量約2
00mlまで濃縮したら、イソプロパノール(300ml)を
加え再濃縮する。約200ml容量まで濃縮されたスラリ
ーを濾過し、濾さい結晶はイソプロパノール(100ml)
で洗浄後、減圧乾燥を行い、粉末の目的化合物を得る。
収量31.52g(61.2mmol)、収率85%。化合物3
’:
TLC Rf=0.50(クロロホルム/酢酸エチル=1
5/1)1
H NMR(CDCl3)δppm; 0.86(s,3H),0.8
7(s,3H),0.91(s,6H),0.99(s,3H),1.15
(s,3H),1.31(s,3H),2.05(s,3H),1.0〜
2.3(m,23H),3.88(br s,1H),4.49(m,1H)13
CNMR(CDCl3)δppm; 16.4,16.5,17.
6,18.6,21.2,21.3,23.6,23.9,27.
5,27.9,28.0,28.7,31.6,33.3,33.
9,34.2,36.4,37.8,38.4,39.3,42.
0,42.3,44.5,44.7,51.1,55.3,76.
0,80.9,90.8,171.2,180.2[0026] 2) Compound 3 'generating synthetic crude product 2' (35.93g, 72mmol) in methylene chloride
(360 ml) -dissolved in methanol (50 ml) mixed solution, -60
Cool to below ℃. Under cooling, ozone gas is introduced until the solution turns purple. Then, nitrogen gas is bubbled, excess ozone is removed (fading), and then concentrated. Capacity about 2
After concentrating to 00 ml, add isopropanol (300 ml) and reconcentrate. The slurry concentrated to a volume of about 200 ml was filtered, and the filtered crystals were isopropanol (100 ml).
After washing with, the product is dried under reduced pressure to obtain the target compound as a powder.
Yield 31.52 g (61.2 mmol), yield 85%. Compound 3 ′: TLC Rf = 0.50 (chloroform / ethyl acetate = 1
5/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.86 (s, 3H), 0.8
7 (s, 3H), 0.91 (s, 6H), 0.99 (s, 3H), 1.15
(s, 3H), 1.31 (s, 3H), 2.05 (s, 3H), 1.0-
2.3 (m, 23H), 3.88 (br s, 1H), 4.49 (m, 1H) 13 CNMR (CDCl 3 ) δ ppm ; 16.4, 16.5, 17.
6,18.6,21.2,21.3,23.6,23.9,27.
5,27.9,28.0,28.7,31.6,33.3,33.
9,34.2,36.4,37.8,38.4,39.3,42.
0,42.3,44.5,44.7,51.1,55.3,76.
0,80.9,90.8,171.2,180.2
【0027】3) 化合物4’の合成
粉末3’(30.98g,60.2mmol)のピリジン(310
ml)溶液を−30〜−40℃に冷却し、ニトロシルクロ
ライド(23.7g,0.36mol)を導入する。1時間攪拌
後、氷水(310ml)を加える。生じたスラリーを濾過
し、濾さいは水(500ml)で洗浄後、塩化メチレン(2
00ml)で再溶解する。無水硫酸マグネシウムで乾燥後n
−ヘキサン(500ml)を加え、容量約100mlまで濃縮
する。生じたスラリーを濾過し、濾さいはn−ヘキサン
(150ml)で洗浄後、減圧乾燥を行い、粉末の目的化合
物を得る。収量32.09g(59.0mmol)、収率98
%。化合物4
’:
TLC Rf=0.74(クロロホルム/酢酸エチル=1
5/1)1
H NMR(CDCl3)δppm; 0.74(s,3H),0.8
5(s,3H),0.86(s,3H),0.91(s,3H),0.93
(s,3H),1.14(s,3H),1.21(s,3H),2.04
(s,3H),0.8〜2.4(m,23H),4.47(dd,J=8.
0,8.0Hz,1H),5.59((dd,J=3.0,2.2Hz,
1H)[0027] 3) in pyridine 'synthetic powder 3' Compound 4 (30.98g, 60.2mmol) (310
solution) is cooled to -30 to -40 ° C and nitrosyl chloride (23.7 g, 0.36 mol) is introduced. After stirring for 1 hour, ice water (310 ml) is added. The resulting slurry was filtered, the filter cake was washed with water (500 ml) and then washed with methylene chloride (2
Redissolve in 100 ml). N after drying over anhydrous magnesium sulfate
-Hexane (500 ml) is added and concentrated to a volume of about 100 ml. The resulting slurry was filtered and filtered using n-hexane.
After washing with (150 ml), it is dried under reduced pressure to obtain a powdery target compound. Yield 32.09 g (59.0 mmol), yield 98
%. Compound 4 ′: TLC Rf = 0.74 (chloroform / ethyl acetate = 1
5/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.74 (s, 3H), 0.8
5 (s, 3H), 0.86 (s, 3H), 0.91 (s, 3H), 0.93
(s, 3H), 1.14 (s, 3H), 1.21 (s, 3H), 2.04
(s, 3H), 0.8 to 2.4 (m, 23H), 4.47 (dd, J = 8.
0,8.0Hz, 1H), 5.59 ((dd, J = 3.0,2.2Hz,
1H)
【0028】4) 化合物5’の合成
粉末4’(4.0g,7.4mmol)のトルエン(200ml)溶
液に窒素ガスを流通し10分間バブリングを行った後、
氷冷する。窒素バブリング,氷冷下,高圧水銀ランプ(4
50W)を45分間照射する。原料4が消失した緑色透
明反応液を、約50ml容量まで濃縮し、その後、80℃
のオイルバスで30分間加熱を行う。次いで、再濃縮
し、カラムクロマトグラフィーにより精製して目的化合
物5を得る。クロマトグラフィー条件:SiO2100g、
クロロホルム/酢酸エチル=10/1→5/1→酢酸エ
チル。収量2.31g(4.2mmol)、収率58%。化合物5
’:
TLC Rf=0.10(クロロホルム/酢酸エチル=1
5/1)1
H NMR(CDCl3)δppm; 0.84(s,6H),0.8
8(s,3H),0.92(s,3H),0.94(s,3H),1.22
(s,3H),2.08(s,3H),0.7〜2.2(m,23H),
3.80(d,9.4Hz,1H),4.20(d,9.4Hz,1H),
4.51(dd,J=11.2,5.4Hz,1H),7.53(s,1
H),8.16(s,1H)[0028] 4) 'Synthesis powder 4' compound 5 (4.0 g, after nitrogen gas was blown into circulation for 10 minutes in toluene (200ml) solution of 7.4 mmol),
Cool on ice. Nitrogen bubbling, under ice cooling, high pressure mercury lamp (4
50W) for 45 minutes. The green transparent reaction liquid from which the raw material 4 has disappeared is concentrated to a volume of about 50 ml, and then 80 ° C
Heat in the oil bath for 30 minutes. Then, it is re-concentrated and purified by column chromatography to obtain the target compound 5 . Chromatographic conditions: 100 g of SiO 2 ,
Chloroform / ethyl acetate = 10/1 → 5/1 → ethyl acetate. Yield 2.31 g (4.2 mmol), yield 58%. Compound 5 ′: TLC Rf = 0.10 (chloroform / ethyl acetate = 1
5/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.84 (s, 6H), 0.8
8 (s, 3H), 0.92 (s, 3H), 0.94 (s, 3H), 1.22
(s, 3H), 2.08 (s, 3H), 0.7 to 2.2 (m, 23H),
3.80 (d, 9.4Hz, 1H), 4.20 (d, 9.4Hz, 1H),
4.51 (dd, J = 11.2, 5.4 Hz, 1 H), 7.53 (s, 1
H), 8.16 (s, 1H)
【0029】5) 化合物6’の合成
粉末5’(13.10g,24mmol)のジオキサン(210m
l)溶液に、酢酸アンモニウム(24.9g,312mmol)、
50%酢酸水(39ml)を加え、氷冷下、三塩化チタン水
溶液(55ml)を滴下する。室温で1.5時間攪拌後、氷
−酢酸エチル(700ml)−10%炭酸ナトリウム(50
0ml)混液にあける。有機層を分取し、水層は酢酸エチ
ルで2回抽出する(300,100ml)。それぞれの有機
層を食塩水で洗浄した後無水硫酸マグネシウムで乾燥
し、濃縮する。残渣を塩化メチレンで溶かし、n−ヘキ
サンを加え、再濃縮する。析出した固体を濾過し、粉末
の目的の新規化合物6’を得る。収量12.01g(23m
mol)、収率94%。化合物6
’:
TLC Rf=0.52(n−ヘキサン/酢酸エチル=1/
1)1
H NMR(CDCl3)δppm; 0.81(s,3H),0.8
3(s,3H),0.89(s,3H),0.92(s,6H),1.26
(s,3H),2.04(s,3H),0.6〜2.3(m,23H),
3.74(d,J=9.4Hz,1H),4.48(dd,J=8.2,
8.2Hz,1H),6.90(br s,1H),8.10(br s,1
H)13
CNMR(CDCl3)δppm; 16.5,16.7,17.
5,18.7,21.2,21.3,23.5,24.0,25.
7,27.0,27.8,27.9,31.6,33.2,33.
8,35.7,36.5,37.8,38.2,40.6,43.
6,43.7,44.7,50.0,53.2,55.5,74.
6,80.5,89.1,171.0,179.3,182.7[0029] 5) 'synthetic powder 5' (13.10 g Compound 6, 24 mmol) in dioxane (210 m
l) solution, ammonium acetate (24.9 g, 312 mmol),
50% Acetic acid water (39 ml) was added, and an aqueous titanium trichloride solution (55 ml) was added dropwise under ice cooling. After stirring at room temperature for 1.5 hours, ice-ethyl acetate (700 ml) -10% sodium carbonate (50
0 ml) Pour into the mixture. The organic layer is separated and the aqueous layer is extracted twice with ethyl acetate (300,100 ml). Each organic layer is washed with brine, dried over anhydrous magnesium sulfate, and concentrated. Dissolve the residue with methylene chloride, add n-hexane, and concentrate again. The precipitated solid is filtered to obtain the target novel compound 6 ′ as a powder. Yield 12.01g (23m
mol), yield 94%. Compound 6 ′: TLC Rf = 0.52 (n-hexane / ethyl acetate = 1 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.81 (s, 3H), 0.8
3 (s, 3H), 0.89 (s, 3H), 0.92 (s, 6H), 1.26
(s, 3H), 2.04 (s, 3H), 0.6 to 2.3 (m, 23H),
3.74 (d, J = 9.4 Hz, 1 H), 4.48 (dd, J = 8.2,
8.2Hz, 1H), 6.90 (br s, 1H), 8.10 (br s, 1
H) 13 CNMR (CDCl 3 ) δ ppm ; 16.5, 16.7, 17.
5,18.7,21.2,21.3,23.5,24.0,25.
7,27.0,27.8,27.9,31.6,33.2,33.
8,35.7,36.5,37.8,38.2,40.6,43.
6,43.7,44.7,50.0,53.2,55.5,74.
6,80.5,89.1,171.0,179.3,182.7
【0030】6) 化合物8’の合成
粉末6’(50mg,0.095mmol)をジオキサン(15m
l)−50%酢酸水混液に溶かし、亜硝酸ナトリウム(1
60mg,2.375mmol)を酢酸ナトリウム(160mg,
1.951mmol)を加える。室温下、30分攪拌後、塩化
メチレン(40ml)−水(10ml)混液にあける。有機層を
分取し、水層は塩化メチレンで抽出する。それぞれの有
機層を食塩水で洗浄した後、無水硫酸マグネシウムで乾
燥し、濃縮して7’と8’の混合粗生成物である濃縮残
渣(62mg)を得る。濃縮残渣をベンゼン(5ml)に溶か
し、中性アルミナ(1g)を加える。加熱還流1.5時間
後、濾過し、濾さい(アルミナ)を塩化メチレン(約30m
l)で洗浄する。このベンゼン−塩化メチレン溶液を濃縮
して、目的化合物8’の粗生成物を得る。収量40mg
(0.076mmol)、収率80%。化合物7
’:
TLC Rf=0.55(n−ヘキサン/酢酸エチル=2/
1)化合物8
’:
TLC Rf=0.45(n−ヘキサン/酢酸エチル=2/
1)1
H NMR(CDCl3)δppm; 0.83(s,6H),0.8
9(s,3H),0.94(s,6H),1.22(s,3H),2.05
(s,3H),0.6〜2.4(m,23H),3.57(d,J=7.
8Hz,1H),3.94(br d,J=7.4Hz,1H),4.4
5(dd,J=10.4,5.8Hz,1H),10.05(s,1H)13
CNMR(CDCl3)δppm; 16.5,17.2,17.
5,18.6,20.9,21.2,21.3,23.5,24.
4,26.9,27.8,31.6,33.1,33.7,36.
3,36.9,37.6,37.8,38.3,43.4,44.
7,46.0,49.9,55.5,58.4,75.3,80.
5,87.1,171.1,179.1,210.0[0030] 6) 'Synthesis powder 6' (50 mg compound 8, 0.095 mmol) in dioxane (15 m
l) Dissolve in 50% acetic acid water mixture and add sodium nitrite (1
60 mg, 2.375 mmol) was added to sodium acetate (160 mg,
1.951 mmol) is added. After stirring at room temperature for 30 minutes, the mixture was poured into a mixed solution of methylene chloride (40 ml) and water (10 ml). The organic layer is separated and the aqueous layer is extracted with methylene chloride. After each of the organic layers were washed with brine, dried over anhydrous magnesium sulfate, to obtain a mixed crude product is a concentrated residue was concentrated 7 'and 8' (62 mg). The concentrated residue is dissolved in benzene (5 ml) and neutral alumina (1 g) is added. After heating under reflux for 1.5 hours, the mixture was filtered, and the residue (alumina) was washed with methylene chloride (about 30 m
Wash with l). The benzene-methylene chloride solution is concentrated to obtain a crude product of the target compound 8 ′. Yield 40mg
(0.076 mmol), yield 80%. Compound 7 ′: TLC Rf = 0.55 (n-hexane / ethyl acetate = 2 /
1) Compound 8 ′: TLC Rf = 0.45 (n-hexane / ethyl acetate = 2 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.83 (s, 6H), 0.8
9 (s, 3H), 0.94 (s, 6H), 1.22 (s, 3H), 2.05
(s, 3H), 0.6 to 2.4 (m, 23H), 3.57 (d, J = 7.
8Hz, 1H), 3.94 (brd, J = 7.4Hz, 1H), 4.4
5 (dd, J = 10.4, 5.8 Hz, 1 H), 10.05 (s, 1 H) 13 CNMR (CDCl 3 ) δ ppm ; 16.5, 17.2, 17.
5,18.6,20.9,21.2,21.3,23.5,24.
4,26.9,27.8,31.6,33.1,33.7,36.
3,36.9,37.6,37.8,38.3,43.4,44.
7,46.0,49.9,55.5,58.4,75.3,80.
5,871.1,171.1,179.1,210.0
【0031】7) 化合物9’の合成
粗生成物8’(90mg,0.17mmol)のピリジン(1ml)
溶液に無水酢酸(0.54g,5.3mmol)とジメチルアミ
ノピリジン(9mg,0.07mmol)を加え、1.5時間の加
熱を行う(油浴85℃)。その後、塩化メチレン(25ml)
−2N塩酸(9ml)混液にあけ、有機層を分取する。水層
は塩化メチレンで抽出し、それぞれの有機層は食塩水で
洗浄する。有機層は無水硫酸マグネシウムで乾燥後、濃
縮し、カラムクロマトグラフィーにより精製して目的物
9’を得る。収量78mg(0.14mmol)、収率80%。化合物9
’:
TLC Rf=0.58(n−ヘキサン/酢酸エチル=2/
1)1
H NMR(CDCl3)δppm; 0.81(s,3H),0.8
3(s,6H),0.92(s,3H),0.93(s,3H),1.21
(s,3H),2.05(s,3H),2.15(s,3H),0.7〜
2.4(m,23H),4.42(dd,J=8.0,4.0Hz,1
H),5.25(br s,1H),10.22(s,1H)7) Synthesis of compound 9 ′ Crude product 8 ′ (90 mg, 0.17 mmol) pyridine (1 ml)
Acetic anhydride (0.54 g, 5.3 mmol) and dimethylaminopyridine (9 mg, 0.07 mmol) were added to the solution, and heating was performed for 1.5 hours (oil bath 85 ° C.). Then methylene chloride (25 ml)
-Pour into a mixture of 2N hydrochloric acid (9 ml) and separate the organic layer. The aqueous layer is extracted with methylene chloride and each organic layer is washed with brine. The organic layer is dried over anhydrous magnesium sulfate, concentrated, and purified by column chromatography to obtain the desired product.
Get 9 '. Yield 78 mg (0.14 mmol), yield 80%. Compound 9 ′: TLC Rf = 0.58 (n-hexane / ethyl acetate = 2 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.81 (s, 3H), 0.8
3 (s, 6H), 0.92 (s, 3H), 0.93 (s, 3H), 1.21
(s, 3H), 2.05 (s, 3H), 2.15 (s, 3H), 0.7 ~
2.4 (m, 23H), 4.42 (dd, J = 8.0,4.0Hz, 1
H), 5.25 (br s, 1H), 10.22 (s, 1H)
【0032】8) 化合物10’(ミリセロール)の合成
−78℃に冷却した液体アンモニア(5ml)に金属リチウ
ム(45mg,6.5mmol)を加え、30分間攪拌溶解す
る。そこへ、原料9’(30mg、0.05mmol)のTHF
溶液を流入し、−78℃下、3時間攪拌する。その後、
塩化アンモニウム(170mg)を加え、反応液が紫から無
色に変化することを確認する。さらに塩化メチレン(2
0ml)を流入後、室温に昇温し、アンモニアを気体とし
て除去し、氷存在下、2N塩酸(10ml)を加える。有機
層を分取し、水層は塩化メチレンで抽出する。それぞれ
の有機層は食塩水で洗浄し、無水硫酸マグネシウムで乾
燥後、濃縮する。残渣はカラムクロマトグラフィーで精
製し目的化合物10’を得る。収量24mg(0.05mmo
l)、収率97%。化合物10
’:
TLC Rf=0.65(n−ヘキサン/酢酸エチル=1/
1)1
H NMR(CDCl3)δppm; 0.70(s,3H),0.7
5(s,3H),0.88(s,3H),0.91(s,3H),0.96
(s,3H),0.98(s,3H),1.0〜2.0(m,22H),
2.91(br d,J=12.4Hz,1H),3.15〜3.26
(m,2H),3.78(d,J=11.8Hz,1H),5.85(br
s,1H)8) Synthesis of compound 10 '(millicerol) Lithium metal (45 mg, 6.5 mmol) was added to liquid ammonia (5 ml) cooled to -78 ° C., and dissolved by stirring for 30 minutes. Raw material 9 '(30 mg, 0.05 mmol) THF
The solution is flowed in and stirred at -78 ° C for 3 hours. afterwards,
Ammonium chloride (170 mg) is added, and it is confirmed that the reaction solution changes from purple to colorless. Furthermore, methylene chloride (2
(0 ml), the temperature was raised to room temperature, ammonia was removed as a gas, and 2N hydrochloric acid (10 ml) was added in the presence of ice. The organic layer is separated and the aqueous layer is extracted with methylene chloride. Each organic layer is washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The residue is purified by column chromatography to obtain the target compound 10 '. Yield 24mg (0.05mmo
l), yield 97%. Compound 10 ′: TLC Rf = 0.65 (n-hexane / ethyl acetate = 1 /
1) 1 H NMR (CDCl 3 ) δ ppm ; 0.70 (s, 3H), 0.7
5 (s, 3H), 0.88 (s, 3H), 0.91 (s, 3H), 0.96
(s, 3H), 0.98 (s, 3H), 1.0 to 2.0 (m, 22H),
2.91 (brd, J = 12.4Hz, 1H), 3.15 to 3.26
(m, 2H), 3.78 (d, J = 11.8Hz, 1H), 5.85 (br
s, 1H)
【0033】実施例3 27−アミノミリセロールの製
造 Example 3 Preparation of 27-Aminomyricerol
【化13】 [Chemical 13]
【0034】9) 化合物11’の合成
実施例2の4)で調製した化合物5’(544mg,1mmo
l)のピリジン(3ml)溶液に無水酢酸(509mg,5mmol)
とジメチルアミノピリジン(54mg,0.44mmol)を加
える。室温下、2時間攪拌後氷−塩化メチレン(20ml)
−6N塩酸(10ml)混液にあける。有機層を分取し、水
層は塩化メチレンで抽出する。それぞれの有機層は食塩
水で洗浄後、無水硫酸マグネシウムで乾燥し濃縮する。
濃縮残渣をカラムクロマトグラフィーで精製し、目的の
新規化合物11’を得る。収量637mg(1.01mmo
l)、収率100%。化合物11
’:
TLC Rf=0.65(塩化メチレン/酢酸エチル=1
0/1)1
H NMR(CDCl3)δppm; 0.80(s,3H),0.8
4(s,3H),0.85(s,3H),0.90(s,3H),0.92
(s,3H),1.25(s,3H),2.06(s,3H),2.17
(s,3H),2.25(s,3H),0.7〜2.4(m,23H),
4.48(m,1H),5.16(br s,1H),8.08(s,1H)9) Synthesis of compound 11 'Compound 5 ' (544 mg, 1 mmo prepared in 4) of Example 2
Acetic anhydride (509 mg, 5 mmol) in a solution of l) in pyridine (3 ml)
And dimethylaminopyridine (54 mg, 0.44 mmol) are added. After stirring at room temperature for 2 hours, ice-methylene chloride (20 ml)
Dip in a 6N hydrochloric acid (10 ml) mixture. The organic layer is separated and the aqueous layer is extracted with methylene chloride. Each organic layer is washed with brine, dried over anhydrous magnesium sulfate and concentrated.
The concentrated residue is purified by column chromatography to obtain the target novel compound 11 '. Yield 637mg (1.01mmo
l), 100% yield. Compound 11 ′: TLC Rf = 0.65 (methylene chloride / ethyl acetate = 1
0/1) 1 H NMR (CDCl 3 ) δ ppm ; 0.80 (s, 3H), 0.8
4 (s, 3H), 0.85 (s, 3H), 0.90 (s, 3H), 0.92
(s, 3H), 1.25 (s, 3H), 2.06 (s, 3H), 2.17
(s, 3H), 2.25 (s, 3H), 0.7-2.4 (m, 23H),
4.48 (m, 1H), 5.16 (br s, 1H), 8.08 (s, 1H)
【0035】10) 化合物12’(27−アミノミリセ
ロール)の合成
−78℃に冷却した液体アンモニア(6ml)に粉末11’
(15mg,0.24mmol)のTHF(2ml)溶液とエタノー
ル(0.5ml)を加える。−78℃下、金属リチウム(91
mg,13.1mmol)を加え、3時間攪拌後、塩化アンモニ
ウム(0.3g)、塩化メチレン(15ml)、メタノール(1
5ml)を加える。昇温してアンモニアを気体として除去
後、氷−塩化メチレン(20ml)−水(15ml)−6N塩酸
(15ml)混液にあける。水層を分取し、酢酸エチル(3
0ml)で抽出する。水層は再び酢酸エチルで抽出し、そ
れぞれの酢酸エチル液は食塩水で洗浄後、無水硫酸マグ
ネシウムで乾燥し、濃縮する。粗生成物として目的化合
物12’を得る。収量52mg(0.11mmol)、収率46
%。化合物12
’:
TLC Rf=0.15(酢酸エチル/酢酸/水=30/
1/1)1
H NMR(CDCl3+CD3OD)δppm; 0.77(s,
3H),0.82(s,3H),0.91(s,3H),0.96(s,3
H),0.98(s,3H),0.99(s,3H),0.7〜2.1
(m,22H),2.67(d,J=14.0Hz,1H),3.01
(br d,J=14.0Hz,1H),3.26(m,2H),5.92
(br s,1H)
上記実施例で製造した化合物を用い、例えば、下記の参
考例に示す方法により、抗エンドセリンレセプター活性
を有するトリテルペン誘導体(III)を製造すること
ができる。10) Synthesis of compound 12 '(27-aminomyricelol) powder 11 ' in liquid ammonia (6 ml) cooled to -78 ° C.
A solution of (15 mg, 0.24 mmol) in THF (2 ml) and ethanol (0.5 ml) are added. Lithium metal (91
mg, 13.1 mmol) was added and after stirring for 3 hours, ammonium chloride (0.3 g), methylene chloride (15 ml), methanol (1
5 ml) is added. After heating to remove ammonia as a gas, ice-methylene chloride (20 ml) -water (15 ml) -6N hydrochloric acid
(15 ml) Pour into the mixture. The aqueous layer was separated and washed with ethyl acetate (3
0 ml). The aqueous layer is extracted again with ethyl acetate, each ethyl acetate solution is washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The target compound 12 'is obtained as a crude product. Yield 52 mg (0.11 mmol), yield 46
%. Compound 12 ′: TLC Rf = 0.15 (ethyl acetate / acetic acid / water = 30 /
1/1) 1 H NMR (CDCl 3 + CD 3 OD) δ ppm ; 0.77 (s,
3H), 0.82 (s, 3H), 0.91 (s, 3H), 0.96 (s, 3)
H), 0.98 (s, 3H), 0.99 (s, 3H), 0.7 to 2.1
(m, 22H), 2.67 (d, J = 14.0Hz, 1H), 3.01
(br d, J = 14.0Hz, 1H), 3.26 (m, 2H), 5.92
(br s, 1H) Using the compounds produced in the above Examples, for example, the triterpene derivative (III) having anti-endothelin receptor activity can be produced by the method shown in the following Reference Example.
【0036】参考例1 ホーナー−エモンズ試薬(化合
物IV)の合成 Reference Example 1 Synthesis of Horner-Emmons reagent (compound IV)
【化14】 [Chemical 14]
【0037】ジメチルホスホノ酢酸(7.07g,42.
1mmol)の塩化メチレン溶液(100ml)に、窒素雰囲
気下室温で塩化チオニル(9.21ml,126mmol)を
加える。室温で4時間撹拌した後に濃縮して酸クロリド
(7.85g)を得る。実施例1で調製した化合物12
(6.60g,14.0mmol)の塩化メチレン溶液(70
ml)に、窒素雰囲気下、−78℃でピリジン(4.53
mL,56mmol)を滴下する。このとき内温は、−73
℃まで上昇した。次いで上で合成した酸クロリド(7.
85g,14.0mmol)の塩化メチレン溶液(70ml)
を25分かけて滴下する。このときの内温は−68℃ま
で上昇した。−75℃で40分間撹拌した後、溶媒を減
圧除去する。残渣をTHF(84ml)に懸濁させ、0℃
に冷却した後、2N NaOH(14ml,28mmol)を加
え、0℃で1時間撹拌する。反応液を氷−1N塩酸(5
0ml)−酢酸エチル(200ml)にあけ、有機層を分取
する。水層を酢酸エチル(150ml×2)で抽出し、そ
れぞれの有機層を食塩水(100ml×2)で洗浄する。
有機層を合わせ、無水硫酸マグネシウムで乾燥し濃縮す
る。カラムクロマトグラフィーにより精製して目的の化
合物(IV)を得る。クロマトグラフィー条件:SiO2
150g,酢酸エチル/ヘキサン=1/1→酢酸エチ
ル→クロロホルム/メタノール=100/1→50/1
→20/1。収量7.43g(11.97mmol,85
%)。Mp.110−113℃、[α]D 22:+83.9
°(c1.01/CHCl3)。化合物(IV) 1
H NMR(CDCl3)δppm:0.80(s,3H),
0.89(s,3H),0.94(s,3H),1.02
(s,3H),1.04(s,3H),1.08(s,3
H),1.0〜2.0(m,20H),2.3〜2.7(m,
2H),2.8〜3.0(m,1H),2.95(d,2JPH
=22.0Hz,2H),3.78(s,3H),3.83
(s,3H),4.13(ABq,Apart,J=12.9
Hz,1H),4.32(ABq,Bpart,J=12.9H
z,1H),5.60(br s,1H)
IR(CHCl3):2944,1728,1696,1
263cm-1 13
C NMR(CDCl3)δppm:15.3,18.0,1
9.5,21.4,22.7,22.8,23.5,23.
7.26.5,30.6,32.2,32.4,32.8,
32.9,33.6,34.0,34.9,37.0,39.
0,39.9,40.8,45.3,46.3,46.4
(d,1JCP=144Hz),47.4,53.1(d,2J
COP=6.4Hz),53.2(d,2JCOP=6.4Hz),
66.8,127.4,137.0,165.3(d,2J
CCP=6.4Hz),183.2,217.3Dimethylphosphonoacetic acid (7.07 g, 42.
To a solution of 1 mmol) in methylene chloride (100 ml) at room temperature under a nitrogen atmosphere is added thionyl chloride (9.21 ml, 126 mmol). After stirring at room temperature for 4 hours, the mixture was concentrated to give acid chloride (7.85 g). Compound 12 prepared in Example 1
A solution of (6.60 g, 14.0 mmol) in methylene chloride (70
ml) under a nitrogen atmosphere at −78 ° C. with pyridine (4.53).
(mL, 56 mmol) is added dropwise. At this time, the internal temperature is -73
It rose to ℃. Then the acid chloride (7.
85 g, 14.0 mmol) in methylene chloride solution (70 ml)
Is added dropwise over 25 minutes. The internal temperature at this time increased to -68 ° C. After stirring for 40 minutes at -75 ° C, the solvent is removed under reduced pressure. The residue was suspended in THF (84 ml), 0 ° C
After cooling to 2, 2N NaOH (14 ml, 28 mmol) is added and stirred at 0 ° C. for 1 hour. The reaction solution was iced-1N hydrochloric acid (5
0 ml) -ethyl acetate (200 ml) and the organic layer is separated. The aqueous layer is extracted with ethyl acetate (150 ml x 2), and each organic layer is washed with brine (100 ml x 2).
The organic layers are combined, dried over anhydrous magnesium sulfate and concentrated. Purification by column chromatography gives the desired compound (IV). Chromatography conditions: SiO 2
150 g, ethyl acetate / hexane = 1/1 → ethyl acetate → chloroform / methanol = 100/1 → 50/1
→ 20/1. Yield 7.43 g (11.97 mmol, 85
%). Mp. 110-113 ° C, [α] D 22 : +83.9
° ( c 1.01 / CHCl 3 ). Compound (IV) 1 H NMR (CDCl 3 ) δ ppm: 0.80 (s, 3H),
0.89 (s, 3H), 0.94 (s, 3H), 1.02
(S, 3H), 1.04 (s, 3H), 1.08 (s, 3
H), 1.0 to 2.0 (m, 20H), 2.3 to 2.7 (m,
2H), 2.8-3.0 (m, 1H), 2.95 (d, 2 J PH
= 22.0 Hz, 2H), 3.78 (s, 3H), 3.83
(S, 3H), 4.13 (ABq, Apart, J = 12.9)
Hz, 1H), 4.32 (ABq, Bpart, J = 12.9H
z, 1H), 5.60 (br s, 1H) IR (CHCl 3 ): 2944, 1728, 1696, 1
263 cm -1 13 C NMR (CDCl 3 ) δppm: 15.3, 18.0, 1
9.5, 21.4, 22.7, 22.8, 23.5, 23.
7.26.5, 30.6, 32.2, 32.4, 32.8,
32.9, 33.6, 34.0, 34.9, 37.0, 39.
0, 39.9, 40.8, 45.3, 46.3, 46.4
(D, 1 J CP = 144 Hz), 47.4, 53.1 (d, 2 J
COP = 6.4 Hz), 53.2 (d, 2 J COP = 6.4 Hz),
66.8, 127.4, 137.0, 165.3 (d, 2 J
CCP = 6.4Hz), 183.2, 217.3
【0038】参考例2 アルデヒド(V)の製造 Reference Example 2 Production of aldehyde (V)
【化15】 [Chemical 15]
【0039】染井ら(Chem.Pharm.Bull.28 2
515(1980))の方法を応用してアルデヒドを合
成した。1gのヒドロキシニトロベンズアルデヒドを2
0mlの酢酸−水(1:1)混液に溶解し、三塩化チタン
水溶液25mlを加える。室温で10分撹拌後水−酢酸エ
チルにあける。水層を炭酸ナトリウム水溶液でpH8と
し、酢酸エチルで抽出する。抽出液を無水硫酸マグネシ
ウムで乾燥後約20mlまで濃縮する。この溶液に氷冷下
ピリジン0.46mlを加え、そこに3−メトキシカルボ
ニルアクリル酸クロリド442mgを加える。0℃で30
分撹拌後、酢酸エチルで抽出する。抽出液を濃縮し、析
出した固体を濾過し、アルデヒド(V)の粉末432mg
(29%収率)を得る。化合物(V) 1
H NMR(CDCl3+CD3OD):3.85(s,
3H),6.91(d,1H,J=15.4Hz),7.1
2(d,1H,J=15.4Hz),7.14(d,1H,
J=2.8Hz),7.18(dd,1H,J=8.8,2.
8Hz),8.58(d,1H,J=8.8Hz),9.86
(s,1H)Somei et al. (Chem. Pharm. Bull. 28 2
515 (1980)) was applied to synthesize an aldehyde. 2g of 1g hydroxynitrobenzaldehyde
It was dissolved in 0 ml of acetic acid-water (1: 1) mixture, and 25 ml of titanium trichloride aqueous solution was added. After stirring at room temperature for 10 minutes, the mixture was soaked in water-ethyl acetate. The aqueous layer is adjusted to pH 8 with aqueous sodium carbonate solution and extracted with ethyl acetate. The extract is dried over anhydrous magnesium sulfate and concentrated to about 20 ml. 0.46 ml of pyridine was added to this solution under ice cooling, and 442 mg of 3-methoxycarbonylacrylic acid chloride was added thereto. 30 at 0 ° C
After stirring for a minute, extract with ethyl acetate. The extract was concentrated, the precipitated solid was filtered, and aldehyde (V) powder 432 mg
(29% yield). Compound (V) 1 H NMR (CDCl 3 + CD 3 OD): 3.85 (s,
3H), 6.91 (d, 1H, J = 15.4Hz), 7.1
2 (d, 1H, J = 15.4Hz), 7.14 (d, 1H,
J = 2.8 Hz), 7.18 (dd, 1H, J = 8.8, 2.
8Hz), 8.58 (d, 1H, J = 8.8Hz), 9.86
(S, 1H)
【0040】参考例3 トリテルペン(III)の合成 Reference Example 3 Synthesis of triterpene (III)
【化16】 [Chemical 16]
【0041】1)化合物(IV)と化合物(V)の縮合
参考例1で得た化合物(IV))621mg(1mmol)と
参考例2で得たアルデヒド(V)299mg(1.2mmo
l)をDMF6mlに溶解する。そこにDBU(ジアサビ
シクロウンデセン)0.358ml,塩化リチウム93mg
を加え室温で1.5時間撹拌を続ける。反応液を酢酸エ
チル抽出し、シリカゲルクロマトグラフィー(クロロホ
ルム/メタノール)にかけ、化合物(IIIa)670
mg(90%収率)を得た。化合物(IIIa) 1
H NMR(CDCl3):0.83(s,3H),0.
84(s,3H),0.93(s,3H),1.03
(s,3H),1.04(s,3H),1.07(s,3
H),1.0−2.1(m,20H),2.2−2.8(m,
2H),2.8−3.0(m,1H),3.84(s,3
H),4.16,4.40(ABq,2H,J=13.0H
z),5.61(br s,1H),6.27(d,1H,J=
16.0Hz),6.90(dd,1H,J=8.8,2.8
Hz),6.94(d,1H,J=15.2Hz),7.07
(d,1H,J=2.8Hz),7.21(d,1H,J=
15.2Hz),7.44(d,1H,J=8.8Hz),
7.74(d,1H,J=16.0Hz)1) Condensation of compound (IV) with compound (V) 621 mg (1 mmol) of compound (IV) obtained in Reference Example 1 and 299 mg (1.2 mmo of aldehyde (V) obtained in Reference Example 2)
l) is dissolved in 6 ml DMF. DBU (diasabicycloundecene) 0.358 ml, lithium chloride 93 mg
Is added and stirring is continued at room temperature for 1.5 hours. The reaction solution was extracted with ethyl acetate and subjected to silica gel chromatography (chloroform / methanol) to give compound (IIIa) 670.
mg (90% yield) was obtained. Compound (IIIa) 1 H NMR (CDCl 3 ): 0.83 (s, 3H), 0.0.
84 (s, 3H), 0.93 (s, 3H), 1.03
(S, 3H), 1.04 (s, 3H), 1.07 (s, 3
H), 1.0-2.1 (m, 20H), 2.2-2.8 (m,
2H), 2.8-3.0 (m, 1H), 3.84 (s, 3
H), 4.16, 4.40 (ABq, 2H, J = 13.0H
z), 5.61 (br s, 1H), 6.27 (d, 1H, J =
16.0 Hz), 6.90 (dd, 1H, J = 8.8, 2.8)
Hz), 6.94 (d, 1H, J = 15.2Hz), 7.07
(D, 1H, J = 2.8Hz), 7.21 (d, 1H, J =
15.2Hz), 7.44 (d, 1H, J = 8.8Hz),
7.74 (d, 1H, J = 16.0Hz)
【0042】次いで、化合物(IIIa)5mg(6.6
μmol)のメタノール300μl溶液に1N−NaOH
100μlを加える。室温で1.5時間撹拌後酢酸エチル
抽出する。抽出液を減圧濃縮し、残渣をシリカゲルクロ
マトグラフィー(酢酸エチル:酢酸:水、30−1−
1)にて精製し、化合物IIIbを3.5mg(収率73
%)得た。さらに、この化合物IIIb21.9mg(0.
03mmol)を水1.2mlに懸濁し、0.1N−NaOH
600μlを加える。生じた溶液を凍結乾燥し、二ナト
リウム塩(化合物IIIc)を21.5mg(93%収
率)得た。Then, 5 mg of compound (IIIa) (6.6)
(1 mol) in 300 μl methanol solution
Add 100 μl. After stirring at room temperature for 1.5 hours, the mixture is extracted with ethyl acetate. The extract was concentrated under reduced pressure, and the residue was subjected to silica gel chromatography (ethyl acetate: acetic acid: water, 30-1-
Purified in 1), 3.5 mg of compound IIIb (yield 73
%)Obtained. Furthermore, this compound IIIb 21.9 mg (0.
(03 mmol) was suspended in 1.2 ml of water, and 0.1 N-NaOH was added.
Add 600 μl. The resulting solution was lyophilized to give the disodium salt (Compound IIIc) 21.5 mg (93% yield).
【0043】IIIb
Rf:0.65(酢酸エチル:酢酸:水;30−1−
1)1
H NMR δppm (CD3OD):0.85(s,3
H),0.87(s,3H),0.94(s,3H),
1.03(s,6H),1.05(s,3H),1.1−
2.0(m,20H),2.3−2.6(m,2H),2.8
−3.0(m,1H),4.11,4.49(ABq,2
H,J=12.6Hz),5.59(br s,1H),6.3
6(d,1H,J=16.0Hz),6.84(d,1H,
J=15.6Hz),6.89(dd,1H,J=8.6,
2.6Hz),7.12(d,1H,J=2.6Hz),7.
14(d,1H,J=8.6Hz),7.20(d,1H,
J=15.6Hz),7.66(d,1H,J=16.0H
z) IIIb Rf: 0.65 (ethyl acetate: acetic acid: water; 30-1-
1) 1 H NMR δppm (CD 3 OD): 0.85 (s, 3
H), 0.87 (s, 3H), 0.94 (s, 3H),
1.03 (s, 6H), 1.05 (s, 3H), 1.1-
2.0 (m, 20H), 2.3-2.6 (m, 2H), 2.8
-3.0 (m, 1H), 4.11, 4.49 (ABq, 2
H, J = 12.6 Hz), 5.59 (br s, 1H), 6.3
6 (d, 1H, J = 16.0Hz), 6.84 (d, 1H,
J = 15.6Hz, 6.89 (dd, 1H, J = 8.6,
2.6 Hz), 7.12 (d, 1H, J = 2.6 Hz), 7.
14 (d, 1H, J = 8.6Hz), 7.20 (d, 1H,
J = 15.6Hz), 7.66 (d, 1H, J = 16.0H
z)
【0044】IIIc 1
H NMR δppm (D2O) DSS(Me3SiCH
2CH2CH2SO3Na) standard,0.73(s,3
H),0.80(s,3H),0.87(s,3H),
0.97(s,3H),1.00(s,6H),1.1−
2.0(m,20H),2.2−2.6(m,2H),2.7
−3.0(m,1H),4.05,4.41(ABq,2
H,J=12.4Hz),5.58(br s,1H),6.3
4(d,1H,J=16.0Hz),6.87,6.92
(ABq,2H,J=16.0Hz),7.00(dd,1
H,J=8.6,2.0Hz),7.19(d,1H,J=
8.6Hz),7.21(d,1H,J=2.0Hz),7.
58(d,1H,J=16.0Hz)
上記参考例で得た化合物は、インビトロおよびインビボ
でエンドリンレセプターに対するエンドセリンの結合を
高度に阻害し、エンドセリンの作用を特異的に抑制す
る。 IIIc 1 H NMR δppm (D 2 O) DSS (Me 3 SiCH
2 CH 2 CH 2 SO 3 Na) standard, 0.73 (s, 3
H), 0.80 (s, 3H), 0.87 (s, 3H),
0.97 (s, 3H), 1.00 (s, 6H), 1.1-
2.0 (m, 20H), 2.2-2.6 (m, 2H), 2.7
-3.0 (m, 1H), 4.05, 4.41 (ABq, 2
H, J = 12.4 Hz), 5.58 (br s, 1H), 6.3
4 (d, 1H, J = 16.0Hz), 6.87, 6.92
(ABq, 2H, J = 16.0Hz), 7.00 (dd, 1
H, J = 8.6, 2.0 Hz, 7.19 (d, 1H, J =
8.6 Hz), 7.21 (d, 1 H, J = 2.0 Hz), 7.
58 (d, 1H, J = 16.0 Hz) The compounds obtained in the above Reference Examples highly inhibit the binding of endothelin to the endrin receptor in vitro and in vivo, and specifically suppress the action of endothelin.
【0045】参考例4 化合物4の酸素存在下での光反
応 Reference Example 4 Photoreaction of Compound 4 in the presence of oxygen
【化17】
光反応装置にアセトン120mlを加え氷冷下酵素ガスを
5分通気する。次に原料1.0g(2.0mmol)を加え
回転子撹拌下溶解させる。高圧水銀ランプ(400W)
にて0.5Hν照射する。(反応温度:5−8℃)。反
応液は、減圧濃縮し、残渣にイソプロパノール2mlを加
えて結晶化する。dp221−222℃を示す27−硝酸
塩0.437g(41.2%)を得た。母液をシリカゲ
ルクロマトで精製し、更に96mg(9.1%)を得た。
合計収率50.3%。この化合物13は新規化合物であ
る。Mp.221−222℃(分解)。
元素分析(C30H45O7Nとして)
計算値:C,67.77;H,8.53;N、2.63
実測値:C,67.29;H,8.49;N,2.56
IRνmax(Nujol):3410, 1749, 1701, 1625, 12
78 cm-1 1
H NMR(CDCl3)δ(200MHz):0.92
(s,3H),0.98(s,3H),0.99(s,3
H),1.05(s,3H),1.11(s,3H),
1.24(s,3H),1.2−2.2(m,20H),
2.5(m,2H,J=7.4Hz),3.9(t,1H,
J=2.6Hz),4.76 5.02(ABq,2H,J
=13Hz)[Chemical 17] 120 ml of acetone was added to the photoreactor, and the enzyme gas was bubbled for 5 minutes under ice cooling. Next, 1.0 g (2.0 mmol) of the raw material is added and dissolved with stirring by a rotor. High pressure mercury lamp (400W)
At 0.5 Hν. (Reaction temperature: 5-8 ° C). The reaction solution is concentrated under reduced pressure, and 2 ml of isopropanol is added to the residue for crystallization. 0.437 g (41.2%) of 27-nitrate having a dp221-222 ° C. was obtained. The mother liquor was purified by silica gel chromatography to give a further 96 mg (9.1%).
Total yield 50.3%. This compound 13 is a novel compound. Mp. 221-222 ° C (decomposition). Elemental analysis (as C 30 H 45 O 7 N) Calculated: C, 67.77; H, 8.53 ; N, 2.63 Found: C, 67.29; H, 8.49 ; N, 2 .56 IRν max (Nujol): 3410, 1749, 1701, 1625, 12
78 cm -1 1 H NMR (CDCl 3) δ (200MHz): 0.92
(S, 3H), 0.98 (s, 3H), 0.99 (s, 3
H), 1.05 (s, 3H), 1.11 (s, 3H),
1.24 (s, 3H), 1.2-2.2 (m, 20H),
2.5 (m, 2H, J = 7.4Hz), 3.9 (t, 1H,
J = 2.6 Hz), 4.76 5.02 (ABq, 2H, J
= 13Hz)
【0046】[0046]
【発明の効果】本発明方法によれば、従来のシロコヤマ
モモからの抽出および化学修飾による製造法に比較し
て、高効率、高収率で、医薬等の合成中間体として極め
て有用なミリセロン誘導体を得ることができる。従っ
て、本発明方法は、最終目的物質の大量生産を推進する
上で大きく貢献するものである。EFFECTS OF THE INVENTION According to the method of the present invention, a mycelone derivative which is highly useful as a synthetic intermediate for medicines and the like with high efficiency and high yield as compared with the conventional method of extraction from whiteberry and chemical modification. Can be obtained. Therefore, the method of the present invention greatly contributes to the mass production of the final target substance.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 Tetrahedron,Suppl ement,(1966),No.7,p. 57−67 (58)調査した分野(Int.Cl.7,DB名) C07J 63/00 C07J 53/00 C07J 75/00 CA(STN) REGISTRY(STN)─────────────────────────────────────────────────── ─── Continued Front Page (56) References Tetrahedron, Supple element, (1966), No. 7, p. 57-67 (58) Fields investigated (Int. Cl. 7 , DB name) C07J 63/00 C07J 53/00 C07J 75/00 CA (STN) REGISTRY (STN)
Claims (7)
方が保護されていてもよいヒドロキシであるか、一緒に
なって保護されていてもよいオキソを形成し、R1はヒ
ドロキシまたはアミノを表す)で示される化合物の製造
方法であって、式(II): 【化2】 (式中、XおよびYは、上記の定義に従い、R2は酸
素、保護されていてもよいヒドロキシイミノまたは保護
されていてもよいイミノ、R3はエステル型ヒドロキシ
保護基を表す)で示される化合物を、アルカリ金属また
はアルカリ土類金属を用いアミン溶液中で還元すること
を特徴とする方法。1. Formula (I): (In the formula, X and Y are hydroxy, in which one is hydrogen and the other is protected, or they together form an optionally protected oxo, and R 1 is hydroxy or A compound represented by the formula (II): (Wherein, X and Y in accordance with the above definitions, R 2 is oxygen, optionally protected hydroxyimino or optionally protected imino, R 3 represents an ester-type hydroxy protecting group) represented by A method comprising reducing a compound with an alkali metal or an alkaline earth metal in an amine solution.
の方法。2. The method according to claim 1, which further comprises a deprotection reaction.
基がアルキルカルボニルまたはアリールカルボニルであ
る請求項1記載の方法。 3. The method according to claim 1, wherein the ester-type hydroxy protecting group for R 3 is alkylcarbonyl or arylcarbonyl.
記載の方法。4. The alkali metal is lithium.
The method described.
保護されたオキソである請求項1記載の方法。5. The method of claim 1 wherein R 2 is oxygen and X and Y are together protected oxo.
よいオキソを形成し、R2は酸素、保護されていてもよ
いヒドロキシイミノまたは保護されていてもよいイミ
ノ、R3は水素またはエステル型ヒドロキシ保護基を表
す)で示される化合物。6. Formula (II): embedded image Wherein X and Y together form an optionally protected oxo, R 2 is oxygen, optionally protected hydroxyimino or optionally protected imino, and R 3 is hydrogen. Or represents an ester type hydroxy protecting group).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10817894A JP3453188B2 (en) | 1994-05-23 | 1994-05-23 | Method for producing oleanolic acid derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10817894A JP3453188B2 (en) | 1994-05-23 | 1994-05-23 | Method for producing oleanolic acid derivative |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003070181A Division JP3682291B2 (en) | 2003-03-14 | 2003-03-14 | Method for producing oleanolic acid derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07316188A JPH07316188A (en) | 1995-12-05 |
JP3453188B2 true JP3453188B2 (en) | 2003-10-06 |
Family
ID=14477977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10817894A Expired - Fee Related JP3453188B2 (en) | 1994-05-23 | 1994-05-23 | Method for producing oleanolic acid derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3453188B2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3054199A (en) * | 1998-04-02 | 1999-10-25 | Nippon Shinyaku Co. Ltd. | Depressant for production of tgf-beta |
TWI232102B (en) | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
MXPA04008944A (en) * | 2002-03-22 | 2004-11-26 | Shionogi & Co | Process for producing triterpene derivative. |
ES2217978B1 (en) * | 2003-04-30 | 2006-03-16 | Consejo Sup. Investig. Cientificas | USE OF OLEANOLIC ACID AS A VASODILATATING AGENT AND RESTORER OF ENDOTELIAL DYSFUNCTION. |
TWI335335B (en) * | 2004-03-24 | 2011-01-01 | Shionogi & Co | A novel crystal of a triterpene derivative |
US8017793B2 (en) | 2004-05-14 | 2011-09-13 | Shionogi & Co., Ltd. | Oxidation of alcohol with use of hydrogen peroxide and tungsten catalyst |
WO2006077801A1 (en) * | 2005-01-18 | 2006-07-27 | Shionogi & Co., Ltd. | Method for preparing myricerone derivative |
KR20110045351A (en) * | 2009-10-26 | 2011-05-04 | 한국과학기술연구원 | A composition for preventing or treating dementia containing oleanoic acid |
CN103242420B (en) * | 2013-05-07 | 2015-02-11 | 南方医科大学 | Friedelane lactone compound and preparation method as well as application thereof |
CN103242416B (en) * | 2013-05-07 | 2015-04-08 | 南方医科大学 | Seco-friedelolactone triterpenoid and preparation method as well as application thereof |
-
1994
- 1994-05-23 JP JP10817894A patent/JP3453188B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Tetrahedron,Supplement,(1966),No.7,p.57−67 |
Also Published As
Publication number | Publication date |
---|---|
JPH07316188A (en) | 1995-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4108130B2 (en) | Stereoselective production method of 4-acetoxyazetidinone | |
JP3453188B2 (en) | Method for producing oleanolic acid derivative | |
JP2691442B2 (en) | Novel proline derivative | |
EP3838894B1 (en) | Method for producing intermediate useful for synethesis of sglt inhibitor | |
CA2205745C (en) | Method for the preparation of baccatin iii and derivatives thereof from 10-deacetylbaccatin iii | |
KR20040043169A (en) | Process for the production of beraprost and its salts | |
IL291468A (en) | A process for the preparation of cortexolone 17alpha-propionate and its new crystalline hydrate | |
JPH09328498A (en) | Production of 24,25-dihydroxycholesterol and its synthetic intermediate | |
JP3682291B2 (en) | Method for producing oleanolic acid derivative | |
US5712263A (en) | Steroid derivatives | |
CN103848874B (en) | The method of the tetra-acetylated-L-gulose of synthesis 1,3,4,6- | |
RU2346948C2 (en) | DERIVATIVES OF 1-α-HALOGEN-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE AND METHOD OF THEIR OBTAINMENT | |
US20090281301A1 (en) | Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate | |
JPWO2003080561A1 (en) | Manufacturing method of voglibose | |
AU2021225706B2 (en) | Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same | |
JP2004505963A (en) | Method for producing discodermolide and its analogues | |
JP3619277B2 (en) | Method for producing dihydropolyprenyl monophosphate and its intermediate compound | |
JP2893473B2 (en) | Process for producing (+)-equilenin and intermediate | |
JP2879776B2 (en) | Method for producing active vitamin D derivative | |
CN117903004A (en) | Synthesis method of Fmoc-a-methyl-L-glutamic acid (5-tert-butyl ester) | |
JPH07224087A (en) | Steroid derivative | |
FI85375C (en) | New process for the preparation of apovincaminol derivatives | |
HU207711B (en) | Process for producing glutaric acid derivatives | |
JP4157175B2 (en) | Method for producing 2'-pyrrolidinepropanoic acid derivative | |
JPS63258872A (en) | Valerolactone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090718 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090718 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100718 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100718 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110718 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |